Revolution Medicines Inc

The U.S. Food and Drug Administration (FDA) on the 26th approved the pancreatic cancer treatment drug "Daraxonrasib," developed by the American biopharmaceutical company Revolution Medicines. It is a once-daily oral tablet that is expected to be a groundbreaking new drug that doubles patient survival time. Pancreatic cancer is difficult to detect and progresses rapidly. An FDA official noted that the approval "provides a new option for patients with cancers that were previously difficult to treat."

Revolution Medicines reported second quarter 2026 financial results and provided updates on its oncology pipeline. The company ended the quarter with $3.9 billion in cash and marketable securities, including $2.2 billion in gross proceeds from concurrent offerings of common stock and convertible notes completed in April 2026 and a $250 million second royalty tranche from Royalty Pharma received in May 2026. Research and development expenses rose to $395 million from $224 million a year earlier, while general and administrative expenses increased to $110 million from $41 million. Net loss for the quarter was $644 million, including a $151 million non-cash charge related to the fair value of warrants from the EQRx acquisition. The company updated its full-year 2026 GAAP operating expense guidance to between $2.1 billion and $2.2 billion, with stock-based compensation expected between $270 million and $290 million. Management highlighted the FDA acceptance of the New Drug Application for daraxonrasib in pancreatic cancer, the initiation of a phased review by the European Medicines Agency, and the expansion of its Expanded Access Program to over 2,000 patients across nearly all 50 U.S. states and Puerto Rico. New clinical data presented included an 82% objective response rate for zoldonrasib in combination with modified FOLFIRINOX in first-line RAS G12D pancreatic cancer and an 85% objective response rate for elironrasib in combination with pembrolizumab and chemotherapy in first-line RAS G12C non-small cell lung cancer.

BeOne Medicines Ltd. and Revolution Medicines, Inc. announced a collaboration in early August 2026 that includes BeOne funding a global Phase 3 trial for Revolution Medicines' RAS(ON) inhibitors. The deal combines BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors and grants BeOne exclusive development and commercialization rights in select Asian markets. This arrangement offloads near-term late-stage costs for Revolution Medicines, which reported a net loss of US$644.37 million for the second quarter of 2026 and US$1,098.19 million over six months. The core catalyst remains regulatory progress and eventual commercialization of daraxonrasib, with ongoing large-scale trial execution and spending still posing significant risk.

Shares of Revolution Medicines have surged more than 134% this year, drawing attention after billionaire Stanley Druckenmiller's Duquesne Family Office bought 316,000 shares in the first quarter. The clinical-stage biotech's lead drug Daraxonrasib doubled median survival to 13.2 months versus 6.7 months for standard chemotherapy in a phase III pancreatic cancer trial, earning FDA Breakthrough Therapy Designation. The company holds $1.9 billion in cash plus $2.1 billion from recent financing to support its pipeline, which targets broad RAS mutations across pancreatic, lung, and colorectal cancers. Revolution is nearing completion of its New Drug Application to the FDA, and the European Medicines Agency initiated an accelerated review this month, with analysts projecting $7 billion in annual sales for Daraxonrasib.

Shares of Revolution Medicines have gained 132% this year, easily outpacing the returns of leading pharmaceutical companies such as Eli Lilly, Johnson & Johnson, and AbbVie. The clinical-stage drugmaker is developing drugs that target cancer-driving proteins once considered undruggable, and its leading candidate daraxonrasib showed a median overall survival of 13.2 months versus 6.7 months for cytotoxic chemotherapy in a head-to-head metastatic pancreatic cancer study. Despite the promise, the company is worth $39 billion with no products on the market and consistent unprofitability, making the valuation look frothy and the stock risky at current levels. The author suggests that a major clinical or regulatory setback could sink the share price and would only consider buying on a significant dip.

The FDA accepted Revolution Medicines' New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, and granted it priority review after the Phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma met all primary and key secondary endpoints. The same data earned daraxonrasib priority pathways on both sides of the Atlantic, including the FDA Commissioner's National Priority Voucher pilot program and high-priority status under the EMA's Cancer Medicines Pathfinder project. The acceptance sharpens the near-term catalyst around a first approval, while upcoming data for zoldonrasib combinations in first-line pancreatic cancer could frame daraxonrasib as part of a broader RAS(ON) franchise. However, high 2026 operating expense guidance and reliance on external capital remain key risks.

Hagens Berman is investigating claims in a securities class action against Erasca, Inc., alleging the company misled investors about its lead oncology candidate ERAS-0015. The litigation claims Erasca used flawed preclinical comparisons to tout superiority over Revolution Medicines' RMC-6236, concealed intellectual property disputes that exposed it to patent infringement and trade secret misappropriation claims, and downplayed safety risks that later included a patient death. On April 27–28, 2026, disclosures of a legal challenge from Revolution Medicines and adverse clinical data triggered a sharp stock decline that wiped out over $2.8 billion in market capitalization. The class period runs from January 14, 2025, to April 26, 2026, and the lead plaintiff deadline is August 10, 2026.

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Erasca, Inc. in the United States District Court for the Southern District of California. The lawsuit covers purchasers of Erasca common stock between January 14, 2025 and April 26, 2026, with a lead plaintiff deadline of August 10, 2026. The complaint alleges that defendants made false and misleading statements regarding ERAS-0015, including that its preclinical data relied on improper comparisons to Revolution Medicines and risked patent and trade secret violations. On April 28, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, causing the stock to drop $9.25 per share, or approximately 48%, from $19.15 to $9.90. Investors who suffered losses can contact the firm at investigations@bespc.com or (212) 355-4648.

Glancy Prongay Wolke & Rotter LLP reminds Erasca, Inc. shareholders of the August 10, 2026 deadline to seek lead plaintiff status in a class action covering purchases of Erasca common stock between January 14, 2025 and April 26, 2026. The lawsuit alleges the company made misleading statements and failed to disclose that its drug candidate ERAS-0015 involved improper preclinical data comparisons to Revolution Medicines and risked patent and trade secret violations. On April 27, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, causing the stock to drop 10.9% to $19.15 per share. After market hours that day, Erasca reported a patient death in a Phase 1 trial of ERAS-0015, sending shares down an additional 48.3% to $9.90 on April 28, 2026.

A new competitive landscape report from DelveInsight reveals that more than 80 active pharmaceutical companies are developing over 90 pipeline molecular glues, with approximately 7 therapies in late-stage development and 15 in mid- or early-stage trials. Key players include Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, Nurix Therapeutics, Monte Rosa Therapeutics, and Neomorph, among others, evaluating candidates such as Daraxonrasib, GT919, CT-01, and NEO-811. The report highlights notable mechanisms of action including RAS(ON) inhibition, GSPT1 degradation, and c-Myc degradation, and covers recent milestones like the FDA’s Breakthrough Therapy Designation for Daraxonrasib and the first patient dosing in Degron Therapeutics’ Phase 1 trial of DEG6498. Approved molecular glues POMALYST and REVLIMID from Bristol Myers Squibb are also profiled, underscoring the class’s established role in multiple myeloma and other hematologic malignancies.

Pomerantz LLP has filed a class action lawsuit against Erasca, Inc. concerning potential securities fraud or unlawful business practices. Investors who purchased or acquired Erasca securities during the Class Period have until August 10, 2026, to seek appointment as Lead Plaintiff. The complaint follows Erasca's April 27, 2026, disclosure of a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation related to ERAS-0015, which caused Erasca's stock to fall 10.71% to $19.50 per share. After market hours that same day, Erasca reported preliminary Phase 1 data for ERAS-0015, including a patient death, and clarified that comparisons to other product candidates were based on cross-study analyses, leading to a further 48.3% drop to $9.90 per share on April 28, 2026.

Hagens Berman is actively investigating claims in a securities class action against Erasca, Inc. The litigation alleges that Erasca and its senior executives misled investors about the competitive advantage, safety profile, and intellectual property surrounding its lead oncology candidate, ERAS-0015, during the class period from January 14, 2025 to April 26, 2026. The complaint claims the company used flawed preclinical comparisons to assert superiority over Revolution Medicines' RMC-6236, concealed patent infringement and trade secret misappropriation risks, and downplayed safety concerns that later included a patient death. On April 27–28, 2026, disclosures of a legal challenge from Revolution Medicines and adverse clinical data triggered a sharp stock decline that wiped out over $2.8 billion in market capitalization. Investors who purchased Erasca common stock during the class period have until August 10, 2026 to seek appointment as lead plaintiff.

Revolution Medicines has seen its stock skyrocket 125% in 2026, and billionaire Stanley Druckenmiller's Duquesne Family Office bought 316,000 shares in the first quarter. The stake was worth $30.6 million at the time of the 13F filing and has since grown to $56.6 million, representing 1% to 2% of the firm's equity portfolio. The company's flagship treatment, Daraxonrasib, has not yet generated revenue or received FDA approval, but positive Phase 3 trial results showing nearly doubled survival rates for metastatic pancreatic cancer patients led to Breakthrough Therapy and Orphan Drug designations. Revolution Medicines is nearing completion of its New Drug Application to the FDA, and the European Medicines Agency launched an accelerated review this month, setting the stage for a potential global launch.

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. securities between January 14, 2025 and April 26, 2026. The lawsuit alleges that Erasca failed to disclose it was at risk of violating patent and trade secret protections, specifically that ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines and placed Erasca at risk of infringement. On April 27, 2026, Erasca disclosed it had received a letter from RevMed’s legal counsel alleging patent infringement and trade secret misappropriation, causing Erasca’s stock price to fall from $21.49 per share on April 24, 2026, to $19.15 per share on April 27, 2026. Shareholders who wish to serve as lead plaintiff must submit their papers to the court by August 10, 2026.

Erasca faces a securities class action after its stock dropped $9.25, or 48%, following disclosures that Revolution Medicines accused Erasca of patent infringement concerning its pan-RAS molecular glue ERAS-0015 and that a patient died one month after receiving the treatment. The lawsuit, filed by Hagens Berman, seeks to represent investors who purchased Erasca common stock between January 14, 2025 and April 26, 2026. The complaint alleges Erasca misled investors by improperly comparing ERAS-0015 to Revolution Medicines' RMC-6236 and by touting intellectual property protection that exposed the company to disputes. On April 27, 2026, Erasca disclosed the patent challenge and the patient death, wiping out over $2.8 billion in market capitalization the next day. The lead plaintiff deadline is August 10, 2026.

Kirby McInerney LLP reminds Erasca, Inc. investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. The lawsuit, filed on behalf of investors who purchased securities between January 14, 2025 and April 26, 2026, alleges that Erasca and its executives made false and misleading statements about its lead oncology drug candidate, ERAS-0015, including improper comparisons to Revolution Medicines' competing drug candidate, RMC-6236, while failing to disclose patent and trade secret risks. On April 27, 2026, Erasca disclosed a letter from RevMed alleging patent infringement and trade secret misappropriation, causing shares to fall 11% from $21.49 to $19.15. A subsequent disclosure of a patient death in a Phase 1 trial and limitations on cross-study comparisons sent shares down an additional 48% to $9.90. Investors who purchased Erasca securities may contact the firm to discuss their rights.

Revolution Medicines announced positive results from two Phase 1/2 trials of zoldonrasib-based combinations in RAS G12D metastatic pancreatic ductal adenocarcinoma. In the RMC-GI-102 trial, zoldonrasib plus modified FOLFIRINOX achieved an 82% objective response rate and 96% disease control rate, while the combination with gemcitabine plus nab-paclitaxel showed 61% and 90%, respectively. The RMC-9805-001 trial of zoldonrasib plus daraxonrasib in previously treated patients demonstrated a 50% objective response rate and 97% disease control rate in the second-line cohort, with median progression-free survival of 9.6 months. In the third-line and later cohort, the objective response rate was 47% and disease control rate was 90%, with median overall survival of 10.5 months. Safety profiles were manageable, with Grade 3 or higher treatment-related adverse events occurring in 61% and 80% of patients in the chemotherapy combination arms, and 35% in the zoldonrasib-daraxonrasib arm.

Revolution Medicines has seen its stock price soar nearly 140% in 2026 following positive late-stage clinical trial results for its lead candidate daraxonrasib in previously treated metastatic pancreatic cancer. The phase 3 trial showed a survival rate of 13.2 months for daraxonrasib compared to 6.7 months for standard chemotherapy, and the company plans to submit these final results for regulatory review. Revolution is also advancing another candidate, zoldonrasib, in phase 3 trials for the same indication, while daraxonrasib is in phase 3 for non-small cell lung cancer and zoldonrasib is entering phase 3 as a combination therapy. The company remains pre-revenue, with a recent quarterly loss of more than $453 million, but holds $1.9 billion in cash and $2.1 billion in net proceeds from financing to support ongoing research and development. Despite the stock's triple-digit gain, some analysts view Revolution as a compelling buy for growth investors due to its novel tri-complex inhibitor platform targeting RAS proteins and its proximity to potential product approval.

Tango Therapeutics is emerging as a key test of precision oncology's value in 2026, centered on MTAP-deleted cancers and synthetic lethality. Its lead asset vopimetostat, an MTA-cooperative PRMT5 inhibitor, is being combined with Revolution Medicines' daraxonrasib and zoldonrasib, as well as Erasca's pan-RAS molecular glue ERAS-0015, in MTAP-deleted, RAS-mutant pancreatic cancer. An early signal from the vopimetostat-daraxonrasib arm showed a 92% objective response rate, 100% disease control rate, and 90% six-month progression-free survival rate among 12 evaluable patients, with plans to advance into late-stage development. Vopimetostat is also in monotherapy studies for MTAP-deleted lung cancer, while brain-penetrant TNG456 is in a phase I/II trial for MTAP-deleted solid tumors including glioblastoma, with data expected in 2026. The stock carries a Zacks Rank #3 (Hold) and a Momentum Score of B, though value and growth scores remain weak.

Pomerantz LLP has filed a class action lawsuit against Erasca, Inc. concerning potential securities fraud or unlawful business practices. Investors who purchased or acquired Erasca securities during the Class Period have until August 10, 2026, to seek appointment as Lead Plaintiff. The lawsuit follows disclosures on April 27, 2026, that Revolution Medicines alleged patent infringement and trade secret misappropriation related to Erasca's ERAS-0015, causing Erasca's stock to fall 10.71% to $19.50 per share. After market hours that same day, Erasca reported preliminary Phase 1 data for ERAS-0015, including a patient death classified as a Grade 3 treatment-related adverse event of pneumonitis that progressed to Grade 5, and acknowledged that comparisons with other product candidates were based on cross-study analyses and not head-to-head trials, leading to a further 48.3% drop to $9.90 per share on April 28, 2026.

Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Erasca, Inc. in the United States District Court for the Southern District of California on behalf of purchasers of Erasca common stock between January 14, 2025 and April 26, 2026. The lawsuit alleges that the company made false and misleading statements and failed to disclose that ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines, Inc., placing Erasca at risk of violating patent and trade secret protections. On April 28, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation related to ERAS-0015, causing the stock to drop 48 percent from $19.15 to $9.90 per share. Investors have until August 10, 2026 to seek lead plaintiff appointment.

Moore Law PLLC is investigating potential claims against officers and directors of Erasca, Inc. over allegations that the company made false or misleading statements about its drug candidate ERAS-0015. The investigation concerns claims that positive statements about ERAS-0015 lacked a reasonable basis, as preclinical data was allegedly based on improper comparisons to Revolution Medicines and placed Erasca at risk of patent and trade secret violations. On April 27, 2026, Erasca disclosed a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, and demanding an end to deceptive comparative statements. Following the news, Erasca’s stock fell from $21.49 per share on April 24 to $19.15 per share on April 27. Shareholders may be able to seek monetary damages and corporate governance reforms on a contingency fee basis.

Revolution Medicines announced it will present clinical data from its RAS(ON) inhibitor pipeline at the 2026 ESMO Gastrointestinal Cancers Congress in Munich from July 1 to 4. The presentations include two oral reports from Phase 1/2 trials of zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for metastatic RAS G12D pancreatic ductal adenocarcinoma. One oral presentation covers zoldonrasib plus chemotherapy in the first-line setting, while the other covers zoldonrasib plus daraxonrasib, the company's oral RAS(ON) multi-selective inhibitor, in patients who had received one or more prior lines of therapy. Two Phase 3 trials-in-progress posters will also be shown: RASolute 303, evaluating daraxonrasib as monotherapy or in combination with gemcitabine and nab-paclitaxel versus standard of care in first-line metastatic PDAC, and RASolute 304, evaluating adjuvant daraxonrasib in patients with resected PDAC who completed perioperative chemotherapy.

Revolution Medicines has started treating patients in the phase III RASolute 305 study, evaluating its investigational oral RAS(ON) G12D-selective inhibitor zoldonrasib in combination with chemotherapy for first-line metastatic RAS G12D pancreatic ductal adenocarcinoma. The global late-stage trial will compare zoldonrasib plus investigator-selected standard-of-care chemotherapy against placebo plus chemotherapy, with co-primary endpoints of progression-free survival and overall survival. Zoldonrasib targets the RAS G12D mutation, which is present in about 40% of PDAC tumors and currently has no approved targeted therapies. Revolution Medicines is also advancing its lead candidate daraxonrasib in the phase III RASolute 303 study for first-line metastatic PDAC, and recently reported positive top-line data from the phase III RASolute 302 study in previously treated patients. Year to date, Revolution Medicines shares have surged 112.9%.

Berger Montague has filed a securities fraud class action lawsuit against Erasca, Inc. on behalf of investors who purchased or acquired Erasca common stock between January 14, 2025 and April 26, 2026. The suit alleges that the company misrepresented its lead drug candidate ERAS-0015 as a potential best-in-class therapy with superior preclinical results compared to Revolution Medicines' RMC-6236. On April 27, 2026, Erasca disclosed accusations of patent infringement and trade secret misappropriation from Revolution Medicines, and reported preliminary clinical data including a patient death while admitting its comparisons relied on cross-study analyses rather than head-to-head trials. Erasca's stock fell more than 45% on the news. Investors have until August 10, 2026 to seek appointment as lead plaintiff.

Faruqi & Faruqi, LLP reminds investors in Erasca, Inc. of the August 10, 2026 deadline to seek lead plaintiff appointment in a securities class action against the company. The lawsuit alleges that Erasca and its executives made false or misleading statements about preclinical data for its drug candidate ERAS-0015, which was based on improper comparisons to Revolution Medicines, Inc.'s proprietary compound, exposing Erasca to patent infringement and trade secret misappropriation claims. On April 27, 2026, Erasca disclosed a letter from RevMed's counsel alleging patent infringement and improper data comparisons, causing its stock to fall roughly 10.9 percent from a closing price of $21.49 on April 24 to $19.15 on April 27. Later that day, Erasca reported preliminary Phase 1 data revealing a patient death classified as a Grade 3 treatment-related adverse event and acknowledged that prior comparisons were not based on head-to-head clinical trials, sending shares down more than 45 percent to close at $9.90 on April 28. Investors who purchased Erasca securities between January 14, 2025 and April 26, 2026 and suffered losses may contact the firm to discuss their legal rights.